LON:CLINClinigen Group Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clinigen Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 525.50 +31.50 (+6.38 %) (As of 04/7/2020 04:00 PM ET) Add Compare Share Today's Range 499Now: GBX 525.50▼ 560.9050-Day Range 357.80MA: GBX 634.78▼ 885.5052-Week Range 350.40Now: GBX 525.50▼ 1,069Volume302,753 shsAverage Volume432,646 shsMarket Capitalization£698.12 millionP/E Ratio50.53Dividend Yield1.36%BetaN/A ProfileAnalyst RatingsAdvanced ChartDividendEarningsInsider TradesHeadlines Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.6 Analyst's Opinion Consensus RatingClinigen Group has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,212.50, Clinigen Group has a potential upside of 130.7% from its current price of GBX 525.50.Amount of Analyst CoverageClinigen Group has only been the subject of 3 research reports in the past 90 days. Previous Next 3.9 Community Rank Outperform VotesClinigen Group has received 411 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClinigen Group has received 115 “underperform” votes. (Add your “underperform” vote.)Community SentimentClinigen Group has received 78.14% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote “Outperform” if you believe CLIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 2.5 Dividend Strength Dividend LeadershipClinigen Group is a leading dividend payer. It pays a dividend yield of 1.36%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthClinigen Group does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Clinigen Group is 0.67 %. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clinigen Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought £41,600 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Clinigen Group are expected to decrease by -100.00% in the coming year, from GBX 2,573 to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clinigen Group is 50.53, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Clinigen Group is 50.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.59.Price to Book Value per Share RatioClinigen Group has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.6Community Rank: 3.9Dividend Strength: 2.5Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.61 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Delivery Sub-IndustryN/A SectorMedical Current SymbolLON:CLIN Previous Symbol CUSIPN/A CIKN/A Webhttp://www.clinigengroup.com/ Phone+44-1283-495010Debt Debt-to-Equity Ratio82.15 Current Ratio1.12 Quick Ratio0.86Price-To-Earnings Trailing P/E Ratio50.53 Forward P/E Ratio0.20 P/E GrowthN/A Sales & Book Value Annual Sales£491.70 million Price / Sales1.42 Cash FlowGBX 31.75 per share Price / Cash Flow16.55 Book ValueGBX 332.40 per share Price / Book1.58Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees849 Outstanding Shares132,849,000Market Cap£698.12 million Next Earnings DateN/A OptionableNot Optionable Receive CLIN News and Ratings via Email Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter. LSE:CLIN Rates by TradingView Clinigen Group (LON:CLIN) Frequently Asked Questions How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)? Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLIN stock has decreased by 20.0% and is now trading at GBX 525.50. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Clinigen Group? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clinigen Group. How were Clinigen Group's earnings last quarter? Clinigen Group PLC (LON:CLIN) released its quarterly earnings data on Tuesday, February, 25th. The company reported $30.80 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $31.00 by $0.20. View Clinigen Group's earnings history. How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group? Clinigen Group declared a dividend on Tuesday, February 25th. Shareholders of record on Thursday, March 19th will be given a dividend of GBX 2.15 per share on Friday, April 17th. This represents a yield of 0.29%. The ex-dividend date of this dividend is Thursday, March 19th. The official announcement can be accessed at this link. View Clinigen Group's dividend history. What price target have analysts set for CLIN? 4 equities research analysts have issued 12-month price objectives for Clinigen Group's stock. Their forecasts range from GBX 790 to GBX 1,500. On average, they anticipate Clinigen Group's share price to reach GBX 1,212.50 in the next year. This suggests a possible upside of 130.7% from the stock's current price. View analysts' price targets for Clinigen Group. Has Clinigen Group been receiving favorable news coverage? News stories about CLIN stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clinigen Group earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutClinigen Group. Who are some of Clinigen Group's key competitors? Some companies that are related to Clinigen Group include ABCAM PLC/ADR (ABCZY), NeoGenomics (NEO), Livongo Health (LVGO), Audentes Therapeutics (BOLD), BridgeBio Pharma (BBIO), PTC Therapeutics (PTCT), Allogene Therapeutics (ALLO), AMN Healthcare Services (AMN), GW Pharmaceuticals PLC- (GWPH), Amicus Therapeutics (FOLD), Agios Pharmaceuticals (AGIO), Dechra Pharmaceuticals (DPH), PPD (SDGR), Medpace (MEDP) and Deciphera Pharmaceuticals (DCPH). What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Application (AAAP), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), Albemarle (ALB), RTI International Metals (RTI), NetApp (NTAP) and StatPro Group (SOG). Who are Clinigen Group's key executives? Clinigen Group's management team includes the following people: Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)Mr. Nicholas Keher, CFO & DirectorMs. Debra Ainge, Chief Operating OfficerMatt Parrish, Head of Investor RelationsMr. David Bryant, Director of Corp. Devel. What is Clinigen Group's stock symbol? Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN." How do I buy shares of Clinigen Group? Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Clinigen Group's stock price today? One share of CLIN stock can currently be purchased for approximately GBX 525.50. How big of a company is Clinigen Group? Clinigen Group has a market capitalization of £698.12 million and generates £491.70 million in revenue each year. Clinigen Group employs 849 workers across the globe. View additional information about Clinigen Group. What is Clinigen Group's official website? The official website for Clinigen Group is http://www.clinigengroup.com/. How can I contact Clinigen Group? Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010. This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is meant by a buy rating?
